drugset / Trial / NCT00282607

A Study of DA-8159 in Subjects With Erectile Dysfunction

NCT00282607

Phase 2 Completed 300 enrolled Dong-A PharmTech Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study will be to evaluate the clinical efficacy and safety of DA-8159, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of subjects with erectile dysfunction (ED).

Timeline

Start
2005-05
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Udenafil Small molecule Oral

Indications